-
3m 54s
-
7m 18sPart 1 Welcome & Programme Overview
-
1h 1m 14s
-
44m 41sPart 3 | Session 1 Critical Moments in Obesity: Early Decisions That Alter Cardiometabolic Risk
-
1h 28m 7sPart 3 | Session 2 Preventing Irreversible Organ Damage: Treating Progressive Obesity
-
1h 29m 14sPart 3 | Session 3 Remodelling Risk: How Obesity Drives CVD and CKD – and How to Intervene
Presentations:
- Future Pharmacology and Combination Strategies – Harold Bays
- Biomarkers and Cardiometabolic Risk Stratification – Naveed Sattar
New Horizons in Obesity Management returned on 17 June 2026 for its third edition, bringing together leading international experts to explore obesity as a central driver of cardio-kidney-metabolic (CKM) disease and a key contributor to multimorbidity across organ systems.
Through a series of practical, evidence-based sessions, faculty examined the latest science, clinical data and treatment strategies shaping modern obesity care. The programme introduced three dedicated specialty tracks – cardiology, primary care and obesity-focused practice – allowing attendees to follow the learning pathway most relevant to their clinical practice or explore the full spectrum of content on demand. Across the sessions, experts discussed lifestyle, pharmacological and procedural approaches, with a focus on translating emerging evidence into real-world patient care.
Led by course directors Dr Angela Fitch (Knownwell, Boston, US), Prof Richard Hobbs (University of Oxford, Oxford, UK) and Prof Nikolaus Marx (University Hospital Aachen, Aachen, DE), the programme featured a distinguished global faculty and explored how earlier intervention, multidisciplinary collaboration and evolving obesity therapies can improve outcomes across the CKM continuum.
Watch the full on-demand series* to catch up on the latest insights, practical guidance and expert discussion from the event.
*Please note, the live version of New Horizons in Obesity Management was accredited. The on-demand version is not.
The symposium 'Real-World Decisions: Implementing Disease-Modifying Obesity Therapy in Primary Care' is available to watch via the link below:
Learning Objectives
- Discuss how obesity drives risk for CKM diseases
- Explain the biological links between obesity and CKM diseases
- Assess how modern obesity medications may modify disease and improve CKM outcomes
- Apply multidisciplinary, translational strategies to improve patient outcomes
- Implement practical strategies to support long-term disease modification and sustained weight loss in real-world settings
- Identify gaps in current care and evaluate emerging therapeutic targets from ongoing clinical trials
Target Audience
- Cardiologists
- Diabetologists
- Endocrinologists
- Nephrologists
- Nurses
- Obesity Specialists
- Primary Care Physicians
More from this programme
Part 1
Welcome & Programme Overview
In this welcome session, Richard Hobbs (Oxford, UK), Angela Fitch (Boston, US) and Nikolaus Marx (Aachen, DE) introduce the programme, share the key learning objectives and outline the clinical priorities shaping the future of obesity management.
| 1 session | |
| Welcome & Programme Overview | Watch now |
Part 2
Session 1 | The CKM Axis Begins With Obesity
In this foundational session, Nikolaus Marx (Aachen, DE), Angela Fitch (Boston, US), Harold Bays (Louisville, US) and Naveed Sattar (Glasgow, UK) examine obesity as the starting point of CKM disease, exploring its biological impact, cardiovascular consequences and evolving treatment strategies.
Part 3
Session 2 | Translating CKM Mechanisms Into Clinical Practice
In this interactive track-based session, expert faculty translate the mechanisms of CKM disease into practical clinical decision-making, exploring how obesity can be addressed across the continuum of risk, from early intervention and risk modification to advanced organ disease management. Choose to follow the pathway most relevant to your practice, or watch all three tracks, led by course directors Richard Hobbs (Oxford, UK), Angela Fitch (Boston, US) and Nikolaus Marx (Aachen, DE).
Part 4
Session 3 | From Silos to Strategy: Coordinating Obesity Care
In this collaborative session, the course directors bring the three specialty tracks back together, exploring how obesity care can be coordinated across disciplines to support timely intervention, aligned decision-making and better outcomes across the CKM continuum.
Part 5
Session 4 | Precision Obesity Care: Biomarkers, Data and the Next Wave of Therapies
In this forward-looking session, Harold Bays (Louisville, US) and Naveed Sattar (Glasgow, UK) explore the next generation of obesity management, examining emerging therapies, combination treatment strategies and the evolving role of biomarkers in personalised cardiometabolic risk assessment.
Part 6
Session 5 | From Evidence to Access: Implementing Obesity Care Across Health Care Systems
In this interactive panel session, Richard Hobbs (Oxford, UK), Luc Van Gaal (Antwerp, BE), Erin Michos (Baltimore, US), Sean Wharton (Toronto, CA) and Ozden Gokdemir (Izmir, TR) discuss the real-world challenges of implementing obesity care, exploring how evidence can be translated into equitable access across different healthcare systems.
Part 7
Session 6 | From Intervention to Impact: Creating a Sustainable Obesity-CKM Ecosystem
In this penultimate session, Nikolaus Marx (Aachen, DE), Richard Hobbs (Oxford, UK), Angela Fitch (Boston, US) and James Burton (Leicester, UK) explore how to build a sustainable obesity–CKM care model, focusing on long-term prevention pathways, organ protection and integrated cardio-kidney management.
Part 8
Key Takeaways and Closing Remarks
In this closing session, the course directors reflect on the key insights and practical takeaways from across the programme, highlighting priorities for advancing obesity management and CKM care in clinical practice.
| 1 session | |
| Key Takeaways and Closing Remarks | Watch now |
Faculty Biographies
Harold Bays
Medical Director and President
Dr Harold Bays is Medical Director and President of the Louisville Metabolic and Atherosclerosis Research Center, US. He has served as a Principal Investigator for over 600 clinical trials of metabolic therapeutic interventions.
Dr Bays is Board Certified in Internal Medicine and Endocrinology and Metabolism, Diplomate of the American Board of Obesity Medicine, and a Diplomate of the American Board of Clinical Lipidology. He is a Fellow of the Obesity Medicine Association, The Obesity Society, the American College of Cardiology, the American Association of Clinical Endocrinologists, the National Lipid Association, and the American Society of Preventive Cardiology.
Dr Bays has written or served as a contributing author to over 350 scientific manuscripts and book chapters and authored/presented 100’s of scientific abstracts.
Naveed Sattar
Professor of Metabolic Medicine
Prof Naveed Sattar is a distinguished Professor of Metabolic Medicine at the renowned Institute of Cardiovascular and Medical Sciences, University of Glasgow. With over two decades of dedicated research and clinical experience, Prof Naveed Sattar has emerged as a leading figure in the field of metabolic medicine and cardiovascular health.
Prof Naveed Sattar's research delves into the origins, evaluation, and treatment of diabetes, obesity, and cardiovascular conditions. Collaborating with various colleagues over the past two decades, he has authored numerous impactful papers, notably with the Emerging Risk Factor Consortium and diabetes registries in Scotland and Sweden. Prof Naveed Sattar has contributed to several lifestyle-focused trials, such as DIRECT, EUROFIT, and UPBEAT, producing mechanistic insights alongside.